Navigation Links
Laureate Pharma Changes Name to Laureate Biopharmaceutical Services, Inc.
Date:1/31/2011

PRINCETON, N.J., Jan. 31, 2011 /PRNewswire/ -- Laureate Pharma, Inc. has changed its name to Laureate Biopharmaceutical Services, Inc. (Laureate Biopharma) to better describe the company's positioning in the biopharmaceutical industry.  The company's logo has been updated to emphasize "Laureate" and to incorporate a laurel wreath, illustrating Laureate Biopharma's reputation for scientific excellence and commitment to delivery.  In addition, the company has established a new homepage (www.lbios.com).  

Laureate Biopharma has been in continuous operation in its Princeton, New Jersey facility since 1981.  Since 1996, Laureate Biopharma has focused exclusively on serving other developers in the biotherapeutics market.  

"We are building on Laureate Biopharma's rich history and adding technologies, capacity and staff, while extending our reputation for quality and delivery," said Michael A. Griffith, Chief Executive Officer.  "This name change, although subtle, speaks to our wealth of experience in protein production and a deep scientific bench, which is unique to the industry."

This name change follows the company's announcement of $20 million in secured capital.  All strategically planned improvements are continuing as previously announced.  These include:

  • Adoption of new quality systems technologies
  • Upgrade of aseptic fill capabilities
  • Upgrade and expansion of protein production facilities and services
  • Expansion of mammalian cell line creation services, and
  • Launch of a contract analytical testing business

For more information related to Laureate Biopharma's capabilities and ongoing improvements please visit them at their new website, www.lbios.com.  

About Laureate Biopharmaceutical Services, Inc.

Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.  For more information, please visit www.lbios.com.

About Saints Capital, LLC

Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit www.saintsvc.com.

For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Biopharmaceutical Services, at (609) 919-3367, or info@lbios.com or visit www.lbios.com or Jennifer Vollaro at Integrated Marketing Services at (609) 683.9055 ext. 247, or jvollaro@imsworld.com


'/>"/>
SOURCE Laureate Biopharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Laureate Pharma Launches New Regulatory Affairs Services and Appoints Robert G. Burford, Ph.D., as Vice President
2. Laureate Pharma Announces New Development and Manufacturing Agreement to Produce AVEO Pharmaceuticals Antibody Therapeutic
3. Elsevier Celebrates Nine 2010 Nobel Laureates and Honors Achievements With Freely Available Prize-Winning Research
4. Laureate Pharma Secures $20 Million to Enhance and Grow Biopharmaceutical Contract Manufacturing Business
5. Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development
6. Thomson Reuters Predicts Nobel Laureates
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
9. Vanda Pharmaceuticals Files Shelf Registration Statement
10. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
11. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Scientists from Silicon Biosystems Menarini today ... door to genetic analysis of previously preserved tumor ... isolate with 100 percent purity. Utilizing the com­pany,s ... various stages of development, the researchers were able ... are clinically relevant, and may change the way ...
(Date:2/11/2016)... 11, 2016  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ... made at the 38th annual John A. Boswick ... which is being held February 14-18, 2016 in ... latest advancements in wound healing, burn care, and infection ... Australian-New Zealand Burns Association, Academy of Physicians in Wound ...
(Date:2/11/2016)... 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced ... a Controlled Equity Offering SM Sales Agreement with ... Macaluso , Chairman and CEO, stated "During our most ... currently raising money and that we have enough money ... still complete all of our current objectives and nothing ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... According to an article published February 1st ... dietary supplement, is being recalled due to the discovery that it contains dangerous adulterants. ... a single supplement on the market proven to help people safety lose excess weight, ...
(Date:2/11/2016)... ... 11, 2016 , ... Dr. Sadati’s recent feature in Allure ... with performing procedures, the magazine also highlights that Dr. Sadati has pioneered new ... the most common procedures he performs is his natural facelift. “As people age, ...
(Date:2/11/2016)... ... 11, 2016 , ... The president released a FY 2017 budget request on ... more of the cost burden to military beneficiaries. , MOAA’s president, retired Air ... budget as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , ...
(Date:2/11/2016)... Irving, Texas (PRWEB) , ... February 11, 2016 ... ... for plastic surgery, dermatology and women’s health, is pleased to announce the promotions ... Practice Development Partners sales team, Steve Catone to executive vice president of North ...
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission for ... the Board of Commissioners. Individuals interested in volunteer board service are encouraged to ... clinical practice settings and across allied health to contribute to its mission and ...
Breaking Medicine News(10 mins):